3De Letter MA,van Doorn PA,Savelkoul HF,et al.Critical illness polyneuropathy and myopathy (CIPNM):evidence for local immune activation by cytokine-expression in the muscle tissue[J].J Neuroimmunol,2000,106(1-2):206-213. 被引量：1
4Stevens R D,Marshall S A,Cornblath D R,et al.A framework for diagnosing and classifying intensive care unit-acquired weakness[J].Crit Care Med,2009,37(10):S299-S308. 被引量：1
5De Jonghe B,Lacherade JC,Sharshar T,et al.Intensive care unit-acquired weakness:risk factors and prevention[J].Crit Care Med,2009,37(10 Suppl):S309-S315. 被引量：1
6Witt NJ,Zochodne DW,Bolton CF,et al.Peripheral-nerve function in sepsis and multiple organ failure[J].Chest,1991,99(1):176-184. 被引量：1
7Berek K,Margreiter J,Willeit J,et al.Polyneuropathies in critically ill patients:a prospective evaluation[J].Intensive Care Med,1996,22(9):849-855. 被引量：1
8Leijten FSS,Weerd AW D,Poortvliet DC J,et al.Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator[J].Intensive Care Med,1996,22(9):856-861. 被引量：1
9De Letter MA,Schmitz PI,Visser LH,et al.Risk factors for the development of polyneuropathy and myopathyin critically ill patients[J].Crit Care Med,2001,29(12):2281-2286. 被引量：1
10Schefold JC,Bierbrauer J,Weber-Carstens S.Intensive care unit-acquired weakness(ICU-AW)and muscle wasting in critically ill patients with severe sepsis and septic shock[J].J Cachexia Sarcopenia Muscle,2010,1(2):147-157. 被引量：1
